Cargando…

Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis

BACKGROUND: Extracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zilong, Ohuchida, Kenoki, Fei, Shuang, Zheng, Biao, Guan, Weiyu, Feng, Haimin, Kibe, Shin, Ando, Yohei, Koikawa, Kazuhiro, Abe, Toshiya, Iwamoto, Chika, Shindo, Koji, Moriyama, Taiki, Nakata, Kohei, Miyasaka, Yoshihiro, Ohtsuka, Takao, Mizumoto, Kazuhiro, Hashizume, Makoto, Nakamura, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537367/
https://www.ncbi.nlm.nih.gov/pubmed/31133044
http://dx.doi.org/10.1186/s13046-019-1226-8
_version_ 1783421990747504640
author Yan, Zilong
Ohuchida, Kenoki
Fei, Shuang
Zheng, Biao
Guan, Weiyu
Feng, Haimin
Kibe, Shin
Ando, Yohei
Koikawa, Kazuhiro
Abe, Toshiya
Iwamoto, Chika
Shindo, Koji
Moriyama, Taiki
Nakata, Kohei
Miyasaka, Yoshihiro
Ohtsuka, Takao
Mizumoto, Kazuhiro
Hashizume, Makoto
Nakamura, Masafumi
author_facet Yan, Zilong
Ohuchida, Kenoki
Fei, Shuang
Zheng, Biao
Guan, Weiyu
Feng, Haimin
Kibe, Shin
Ando, Yohei
Koikawa, Kazuhiro
Abe, Toshiya
Iwamoto, Chika
Shindo, Koji
Moriyama, Taiki
Nakata, Kohei
Miyasaka, Yoshihiro
Ohtsuka, Takao
Mizumoto, Kazuhiro
Hashizume, Makoto
Nakamura, Masafumi
author_sort Yan, Zilong
collection PubMed
description BACKGROUND: Extracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer–stromal interaction. METHODS: Immunohistochemistry and western blotting were performed to detect the expression of p-ERK1/2 in pancreatic tissues and cells. Cell viability assay was used to study IC50 of ERK inhibitor on pancreatic cancer cells (PCCs) and primary cancer-associated pancreatic stellate cells (PSCs). Transwell migration, invasion, cell viability assay, senescence β-galactosidase staining were performed to determine the effect of ERK inhibitor on PCCs and PSCs in vitro and in vivo. The expression of key factors involved in autophagy and epithelial-to-mesenchymal transition (EMT) process were evaluated by western blotting. The expression of key factors related to cell invasiveness and malignancy were confirmed by qRT-PCR. Co-transplantation of PCC Organoid and PSC using a splenic xenograft mouse model was used to evaluated combined treatment of ERK inhibitor and autophagy inhibitor. RESULTS: Immunohistochemical staining in pancreatic tumor samples and transgenetic mice detected p-ERK1/2 expression in both cancer cells and stromal cells. In pancreatic tissues, p-ERK1/2 was strongly expressed in cancer-associated PSCs compared with cancer cells and normal PSCs. PSCs were also significantly more sensitive to ERK1/2 inhibitor treatment. Inhibition of ERK1/2 suppressed EMT transition in HMPCCs, upregulated cellular senescence markers, activated autophagy in cancer-associated PSCs; and suppressed cancer–stromal interaction, which enhanced invasiveness and viability of cancer cells. We also found that chloroquine, an autophagy inhibitor, suppressed ERK inhibition-induced autophagy and promoted PSC cellular senescence, leading to significantly decreased cell proliferation. The combination of an ERK inhibitor and autophagy inhibitor suppressed liver metastasis in a splenic pancreatic cancer organoid xenograft mouse model. CONCLUSIONS: These data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-019-1226-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6537367
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65373672019-05-30 Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis Yan, Zilong Ohuchida, Kenoki Fei, Shuang Zheng, Biao Guan, Weiyu Feng, Haimin Kibe, Shin Ando, Yohei Koikawa, Kazuhiro Abe, Toshiya Iwamoto, Chika Shindo, Koji Moriyama, Taiki Nakata, Kohei Miyasaka, Yoshihiro Ohtsuka, Takao Mizumoto, Kazuhiro Hashizume, Makoto Nakamura, Masafumi J Exp Clin Cancer Res Research BACKGROUND: Extracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer–stromal interaction. METHODS: Immunohistochemistry and western blotting were performed to detect the expression of p-ERK1/2 in pancreatic tissues and cells. Cell viability assay was used to study IC50 of ERK inhibitor on pancreatic cancer cells (PCCs) and primary cancer-associated pancreatic stellate cells (PSCs). Transwell migration, invasion, cell viability assay, senescence β-galactosidase staining were performed to determine the effect of ERK inhibitor on PCCs and PSCs in vitro and in vivo. The expression of key factors involved in autophagy and epithelial-to-mesenchymal transition (EMT) process were evaluated by western blotting. The expression of key factors related to cell invasiveness and malignancy were confirmed by qRT-PCR. Co-transplantation of PCC Organoid and PSC using a splenic xenograft mouse model was used to evaluated combined treatment of ERK inhibitor and autophagy inhibitor. RESULTS: Immunohistochemical staining in pancreatic tumor samples and transgenetic mice detected p-ERK1/2 expression in both cancer cells and stromal cells. In pancreatic tissues, p-ERK1/2 was strongly expressed in cancer-associated PSCs compared with cancer cells and normal PSCs. PSCs were also significantly more sensitive to ERK1/2 inhibitor treatment. Inhibition of ERK1/2 suppressed EMT transition in HMPCCs, upregulated cellular senescence markers, activated autophagy in cancer-associated PSCs; and suppressed cancer–stromal interaction, which enhanced invasiveness and viability of cancer cells. We also found that chloroquine, an autophagy inhibitor, suppressed ERK inhibition-induced autophagy and promoted PSC cellular senescence, leading to significantly decreased cell proliferation. The combination of an ERK inhibitor and autophagy inhibitor suppressed liver metastasis in a splenic pancreatic cancer organoid xenograft mouse model. CONCLUSIONS: These data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-019-1226-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-27 /pmc/articles/PMC6537367/ /pubmed/31133044 http://dx.doi.org/10.1186/s13046-019-1226-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yan, Zilong
Ohuchida, Kenoki
Fei, Shuang
Zheng, Biao
Guan, Weiyu
Feng, Haimin
Kibe, Shin
Ando, Yohei
Koikawa, Kazuhiro
Abe, Toshiya
Iwamoto, Chika
Shindo, Koji
Moriyama, Taiki
Nakata, Kohei
Miyasaka, Yoshihiro
Ohtsuka, Takao
Mizumoto, Kazuhiro
Hashizume, Makoto
Nakamura, Masafumi
Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title_full Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title_fullStr Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title_full_unstemmed Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title_short Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
title_sort inhibition of erk1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537367/
https://www.ncbi.nlm.nih.gov/pubmed/31133044
http://dx.doi.org/10.1186/s13046-019-1226-8
work_keys_str_mv AT yanzilong inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT ohuchidakenoki inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT feishuang inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT zhengbiao inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT guanweiyu inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT fenghaimin inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT kibeshin inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT andoyohei inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT koikawakazuhiro inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT abetoshiya inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT iwamotochika inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT shindokoji inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT moriyamataiki inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT nakatakohei inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT miyasakayoshihiro inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT ohtsukatakao inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT mizumotokazuhiro inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT hashizumemakoto inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis
AT nakamuramasafumi inhibitionoferk12incancerassociatedpancreaticstellatecellssuppressescancerstromalinteractionandmetastasis